Telo Genomics Retains Former Abbott & Siemens Veteran Gregg Mayer to Lead the Development of the Company’s Industry Partnership Strategy
TORONTO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that the Company has entered into a consulting agreement with the biomedical industry veteran Gregg Mayer, Founder & Principal of BioCore Strategies, LLC, Boston, Massachusetts, USA, and former executive of Abbott Diagnostics, Siemens and a number of early-stage biopharma and medical device companies, both public and privately held. Mr. Mayer will lead TELO’s efforts to develop and execute the Company’s industry partnership strategy with Biopharma and Diagnostics industries.
“I have previously collaborated with Gregg and am thrilled to have him onboard leading Telo Genomics efforts to develop the Company’s industry partnership strategy,” said Guido Baechler, TELO Chairman. “Gregg brings 35 years of executive experience in the biomedical industry, particularly in crafting diagnostics-pharma partnerships”.
Mr. Mayer founded BioCore Strategies, LLC in 2010, a Massachusetts-based consultancy to help small/mid-size companies develop and commercialize innovative medical technologies. Since 1984 Mr. Mayer held key executive and expert consulting roles with several pharmaceutical and medical device companies. In these roles, Mr. Mayer focused on the design, development, and commercialization of innovative diagnostics technologies, and has led numerous collaborations with biopharma industry. He was elected Chairman of the Medical Imaging Contrast Agent Association (MICAA), a Washington DC-based lobby group focused on regulatory and reimbursement policy. Gregg earned a Bachelor of Business Administration degree from the University of Texas at Austin, and an MBA from Northwestern University’s Kellogg School of Management.
“I am excited to work with the Telo Genomics team” said Gregg Mayer. “The TeloView® technology is unique and innovative, with the added advantage of delivering single-cell analytics to a liquid biopsy platform. These leading-edge characteristics will help in establishing new partnerships with biopharma & diagnostics companies driving precision medicine to identify patients who will benefit from a specific treatment, predict patient response to treatment, and monitor treatment outcomes over time.”
In connection with the consulting agreement issued between TELO and Gregg Mayer, the Company has granted Mr. Mayer 120,000 of Company’s stock options vesting over 6 months at an exercise price of $0.49 per stock option in accordance to TELO’s approved stock options plan and subject to final TSXV approval.
About Telo Genomics
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team’s considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer’s disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information please visit www.telodx.com.
For further information, please contact:
Hugh Rogers, Director
MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto, ON, M5G 1L7
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “intends”, “will”, or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the clinical efficacy of products, commercial viability of products, use of proceeds, and the ability of the TeloViewTM platform to deliver personalized medicine resulting in better treatments and outcomes are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.